Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for AVTX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 52.90M
March 31, 2026 24.64M
December 31, 2025 18.51M
September 30, 2025 17.83M
June 30, 2025 10.84M
March 31, 2025 10.83M
December 31, 2024 10.47M
September 30, 2024 9.682M
June 30, 2024 1.034M
March 31, 2024 1.034M
December 31, 2023 0.8017M
September 30, 2023 0.8016M
June 30, 2023 0.0585M
March 31, 2023 0.055M
December 31, 2022 0.0393M
September 30, 2022 0.0392M
June 30, 2022 0.0392M
March 31, 2022 0.0392M
December 31, 2021 0.0392M
September 30, 2021 0.039M
June 30, 2021 0.0333M
March 31, 2021 0.0309M
December 31, 2020 0.026M
September 30, 2020 0.026M
Date Value
June 30, 2020 0.026M
March 31, 2020 0.0207M
September 30, 2019 0.0153M
June 30, 2019 0.0149M
March 31, 2019 0.0148M
December 31, 2018 0.0142M
September 30, 2018 0.0141M
June 30, 2018 0.0117M
March 31, 2018 0.0109M
December 31, 2017 0.0109M
September 30, 2017 0.009M
June 30, 2017 0.0049M
March 31, 2017 0.0038M
December 31, 2016 0.0033M
September 30, 2016 0.0032M
June 30, 2016 0.003M
March 31, 2016 0.003M
December 31, 2015 0.003M
September 30, 2015 0.003M
June 30, 2015 0.003M
March 31, 2015 0.003M
June 30, 2014 0.003M
March 31, 2014 0.003M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 172.13M
Incyte Corp. 200.98M
AbbVie, Inc. 1.767B
Rezolute, Inc. 96.29M
Alnylam Pharmaceuticals, Inc. 133.73M